Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Palpable Subcutaneous Malignant Lesions: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Palpable Subcutaneous Malignant Lesions: 1 US clinical trial tracked, none currently recruiting.

Palpable Subcutaneous Malignant Lesions is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Toray Industries, running 1 of these trials.

Enrollment posture brief

Registry condition palpable-subcutaneous-malignant-lesions

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Palpable Subcutaneous Ma (th…0%
Open-enrollment share among volume-matched conditions near Palpable Subcutaneous Malignant Lesions

Palpable Subcutaneous Malignant Lesions has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Palpable Subcutaneous Malignant Lesions on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Palpable Subcutaneous Malignant Lesions is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Toray Industries 1 trials

Named interventions

Most-linked intervention names on Palpable Subcutaneous Malignant Lesions records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

TRK-950 Biological
1 trials
Irinotecan Drug
1 trials
Leucovorin Drug
1 trials

US sites by state

Facility locations filed on Palpable Subcutaneous Malignant Lesions trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
Virginia 1 trials
Texas 1 trials
Oregon 1 trials
New York 1 trials
New Jersey 1 trials
Louisiana 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Palpable Subcutaneous Malignant Lesions page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Palpable Subcutaneous Malignant Lesions trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Toray Industries sponsors the most Palpable Subcutaneous Malignant Lesions trials on record, review their full trial history before evaluating a specific study. See Toray Industries's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Palpable Subcutaneous Malignant Lesions condition card totals 1 registered trials; most-linked intervention TRK-950; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.